Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 32,500 full-time employees.  The company is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.

Bristol Myers Squibb Co. terlibat dalam penemuan, pengembangan, perizinan, pembuatan, pemasaran, distribusi, dan penjualan produk biofarmasi. Perusahaan ini bermarkas di Princeton, New Jersey dan saat ini mempekerjakan 32.500 karyawan penuh waktu. Perusahaan ini terlibat dalam penemuan, pengembangan, dan pengiriman obat-obatan transformatif bagi pasien yang menghadapi penyakit serius di bidang: onkologi, hematologi, imunologi, kardiovaskular, ilmu saraf, dan area lainnya. Portofolio pertumbuhannya mencakup Opdivo (nivolumab), Opdivo Qvantig (nivolumab dan hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab dan relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), dan Sotyktu (deucravacitinib). Produk pertumbuhan lainnya termasuk Onureg, Inrebic, dan Empliciti. Portofolio warisan mencakup Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), dan Abraxane (partikel paclitaxel terikat albumin untuk suspensi injeksi). Opdivo (nivolumab) adalah antibodi monoklonal manusia sepenuhnya yang mengikat pada PD-1 pada sel T dan sel NKT.

Bristol-Myers Squibb

Google

Apple

Microsoft

Amazon

Broadcom

Meta Platforms

Eli Lilly

JPMorgan

Oracle

Exxon Mobil

Johnson & Johnson

ASML

MasterCard

SPDR S&P500 ETF

Palantir

Costco

Bank of America

General Electric

Procter & Gamble

Vanguard Total Stock Market ETF

Toyota

Caterpillar

AstraZeneca

Cisco

Goldman Sachs

Lam Research

Wells Fargo

Merck

Novo Nordisk

Novartis

Raytheon Technologies

Philip Morris

Applied Materials

American Express

Royal Bank of Canada

Intel

Abbott

Salesforce

Shell

T-Mobile

Intuitive Surgical

Disney

Shopify

Invesco QQQ Trust

Blackstone

PepsiCo

Boeing

Charles Schwab

Amgen

QUALCOMM

Texas Instruments

S&P Global

Verizon

Arista Networks

Lowe's

Capital One

Southern Copper

Honeywell

Sony

Pfizer

Unilever

Deere

TotalEnergies

ServiceNow

Adobe

Palo Alto Networks

ConocoPhillips

Medtronic

Progressive

Chubb

CrowdStrike

Sanofi

Vertex Pharmaceuticals

Comcast

Vanguard Dev Markets ETF

Mercadolibre

Starbucks

Enbridge

Carvana

Agnico Eagle

General Dynamics

Vanguard Value ETF

Robinhood

Moody's

Nike

Northrop Grumman

Vanguard Total Bond Market ETF

Duke Energy

Scotiabank

Barclays

Doordash Inc

Marsh & McLennan

NetEase

Bristol-Myers Squibb Stock

About Bristol-Myers Squibb

Key Statistics

People Also Bought